Department of Biomedical Informatics, University of Utah, Salt Lake City, UT 84112, USA.
Am J Health Syst Pharm. 2013 Aug 1;70(15):1301-12. doi: 10.2146/ajhp130049.
Outbreaks of health-care-associated infections related to compounding pharmacies from 2000 through 2012 are described.
PubMed and the websites for the Centers for Disease Control and Prevention and the Food and Drug Administration were searched to identify infectious outbreaks associated with compounding pharmacies outside the hospital setting between January 2000 and November 2012.
Between January 2000 and before the 2012 fungal meningitis outbreak, 11 outbreaks were identified, involving 207 infected patients and 17 deaths after exposure to contaminated compounded drugs. The 2012 meningitis outbreak had a similar mortality rate but increased these totals almost fivefold. Half of the outbreaks involved patients in more than one state. Three outbreaks involved ophthalmic drugs. The remaining outbreaks involved corticosteroids, heparin flush solutions, cardioplegia solution, i.v. magnesium sulfate, total parenteral nutrition, and fentanyl. The outbreaks were caused by pathogens commonly associated with health-care-associated infections, common skin commensals, and organisms that rarely cause infection. Morbidity was substantial, including vision loss. Half the outbreaks resulted in recall of all sterile drugs from the pharmacy due to systemic problems with sterile procedures.
Before the nationwide 2012 fungal meningitis outbreak, drugs produced by compounding pharmacies were associated with 11 other smaller, but equally serious, outbreaks that occurred sporadically over the past 12 years. Lapses in sterile compounding procedures led to contamination of compounded drugs, exposure to patients, and a threat to public health in these outbreaks. Recognition and subsequent public health investigation were usually triggered by the occurrence of illness among multiple patients in a single health care setting.
描述 2000 年至 2012 年间与 compounding 药房相关的医源性感染爆发情况。
检索 PubMed 以及美国疾病控制与预防中心和美国食品药品监督管理局的网站,以确定 2000 年 1 月至 2012 年 11 月期间非医院环境下与 compounding 药房相关的传染性爆发事件。
2000 年 1 月至 2012 年真菌性脑膜炎爆发之前,共发现 11 起爆发事件,涉及 207 名感染患者,其中 17 人在接触受污染的复合药物后死亡。2012 年脑膜炎爆发事件的死亡率相似,但将这些数字增加了近五倍。一半的爆发事件涉及多个州的患者。有 3 起爆发事件涉及眼科药物。其余爆发事件涉及皮质类固醇、肝素冲洗液、心脏停搏液、静脉注射硫酸镁、全胃肠外营养和芬太尼。这些爆发事件是由与医源性感染相关的常见病原体、常见皮肤共生菌以及很少引起感染的病原体引起的。发病率相当高,包括视力丧失。一半的爆发事件因无菌操作的系统性问题导致该药房所有无菌药物召回。
在全国性的 2012 年真菌性脑膜炎爆发之前,compounding 药房生产的药物与过去 12 年间零星发生的另外 11 起较小但同样严重的爆发事件有关。无菌复合操作失误导致复合药物污染、暴露于患者并在这些爆发事件中对公众健康构成威胁。通常是在单一医疗机构中多个患者出现疾病后才会识别并随后进行公共卫生调查。